What is the revenue and EPS growth rate for IGC Pharma year over year?

What guidance did IGC Pharma's management provide for the next earnings period?

What is IGC Pharma's latest dividend and current dividend yield?

Did IGC Pharma beat or miss consensus estimates last quarter?

What is IGC Pharma's gross profit margin?

What is the market's earnings forecast for IGC Pharma next quarter?

What factors drove the changes in IGC Pharma's revenue and profit?

What were the key takeaways from IGC Pharma’s earnings call?

- **Key Drug Candidate Progress**: IGC 81 reduces agitation in 2 weeks vs. 10 weeks for existing treatments.
- **Clinical Trial Expansion**: 35 sites across U.S. and Canada with 50% enrollment.
- **Cost Management**: Divested non-core assets to reduce expenses.
- **AI Innovation**: MINT-AD predicts Alzheimer's risk using multimodal data.
- **2026 Focus**: Complete phase two trial and advance pipeline.


**【CEO Summary Section】**
- IGC Pharma is advancing five Alzheimer's drug candidates, with IGC 81 in phase two CALMA trial targeting agitation in Alzheimer's patients.
- IGC 81 shows interim results reducing agitation in two weeks vs. existing medications' 6-10 week timeline.
- Expanded clinical trial sites in U.S. and Canada, with 50% enrollment completion.
- Preclinical data demonstrates IGC 81 targets amyloid plaques and tau tangles.
- MINT-AD AI platform predicts Alzheimer's risk and cognitive decline.
- Strategic divestment of non-core manufacturing assets to reduce costs.
- Focus on completing phase two trial and advancing pipeline.

**【CFO Financial Commentary】**
- Sold non-core manufacturing facility to reduce $600k annual expenses.
- Secured 10% future sale contingent rights.
- Maintaining $12M credit line and selective capital raises.
- Focus on cost-efficient clinical trial execution.

**【Q&A Highlights】**
- No further interim data releases planned before final readout.
- Trial expansion to 35 sites accelerates enrollment (14 patients/month).
- Regulatory changes to hemp industry不影响 prescription drug pipeline.
- Social media recruitment drives 14 new patients/month.
- AI platform in semifinal for $1M Alzheimer's research prize.
- 2026 milestones: complete CALMA trial, expand pipeline, deploy MINT-AD.


IGC

IGC fundamentals

Earnings Call

You can ask Aime